Raymond James Downgrades Exact Sciences to Outperform, Lowers Price Target to $130
Raymond James analyst Andrew Cooper downgrades Exact Sciences (NASDAQ:EXAS) from Strong Buy to Outperform and lowers the price target from $160 to $130.
Exact Sciences Q3 Adj. EPS $(0.79) Beats $(0.85) Estimate, Sales $456.38M Beat $430.03M Estimate
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.85) by 7.06 percent. This is a 1028.57 percent decrease over losses of $(0.07) per share from
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Cathie Wood’s ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM
Intellia Therapeutics (NTLA) - 34,200
Pacific Biosciences of California (PACB) - 119,183
Archer Aviation (ACHR) - 591,618
MarkForged Holding Corp (MKFG) - 76,612
Blade
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Why Exact Sciences’ Stock Is Trading Higher Today
Exact Sciences (NASDAQ:EXAS) shares are trading higher after the company announced an expansion of its primary care sales team with the addition of former Pfizer sales representatives.
Exact Sciences 8-K Shows Co. Expanded Its Primary Care Sales Team To Increase Adoption Of Cologuard, Its Pipeline Of Cancer Screening Tests
On September 15, 2021, Exact Sciences Corporation (“Exact Sciences”) announced it has expanded its primary care sales team to increase adoption of Cologuard®, the first and only FDA-approved, at-home
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announced Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
Exact Sciences Corp. (NASDAQ: EXAS) announced today that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative group founded by the National Cancer Institute (NCI).
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices.
A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five years and went from small-cap to a market cap of more than $18 billion.